VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
The former president experienced Parkinson’s-like symptoms
5 days ago
Smartphone test predicts development of Parkinson’s symptoms, study says
Researchers have created a smartphone test that may be able to predict the development of Parkinson’s symptoms. The study – carried out by researchers from the University of Oxford and funded by the Monument Trust Discovery Award from charity Parkinson’s UK – used the test to assess voice, balance, walking and reaction time in people living with Parkinson’s. The results indicated that the test may be able to predict development of Parkinson’s symptoms up to 18 months before they occur. Researchers hope this will allow healthcare professionals to tailor a more personalised approach to the treatment of Parkinson’s. Christine Lo, clinical research fellow at the University of Oxford’s Oxford Parkinson’s Disease Centre, said: “The main driver for this study was to improve clinical care by finding better ways of predicting how Parkinson’s is likely to progress over time on an individual basis, as its course can vary greatly from person to…
The European Parkinson’s Disease Association (EPDA) is inviting carers from within the Parkinson’s community to take part in a survey aiming to shine a light on the physical, financial and emotional difficulties they face. The research – supported by French healthcare devices company Air Liquide – will be used to inform future campaigns and create valuable tools to help carers and the wider Parkinson’s community. Russell Patten, the secretary general of the EPDA, said: “Carers are such an important part of the Parkinson’s community – they provide the firm foundations that support their loved ones who are physically living with the condition. “However, carers’ needs and quality of life are sadly, all too often, overlooked; this can lead to devastating and lasting effects on the individual and the wider society.” The survey is open until 6 September 2019, and is available in English, French, German Italian, Danish, Dutch, Portuguese, Slovenian…
Scottish university reveals multimillion-pound Parkinson’s research partnership
The University of Dundee, UK, has announced a collaboration with South Korean pharmaceutical company Bukwang to develop a new treatment for Parkinson’s. Collaborating with researchers at the University of Oxford, UK, the university’s drug discovery unit (DDU) has found molecules that may reduce levels of a protein closely connected to the development of the condition. The new partnership will build on this existing relationship between the universities – and facilitate a further three-year Parkinson’s research programme which will move the molecules towards clinical development. Professor Paul Wyatt, head of the DDU, said: “Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together. “This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug-discovery capabilities, allowing us to move one stage further towards a treatment.”